Cover Image
市場調查報告書

氨基酸企業的產業的方向性

Business Direction of Amino Acid Companies

出版商 CCM 商品編碼 320373
出版日期 內容資訊 英文 39 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
氨基酸企業的產業的方向性 Business Direction of Amino Acid Companies
出版日期: 2014年11月28日 內容資訊: 英文 39 Pages
簡介

氨基酸(特別是離胺酸、甲硫胺酸)的散裝容量,在全世界持續增加,市場上競爭激烈。

本報告提供氨基酸的主要企業相關研究、國內/海外的生產企業的業績和經營計劃相關驗證等有系統的資訊。

第1章 概要

第2章 國內企業

  • Fufeng Group
    • 企業簡介
    • 業績
    • 未來發展
  • Meihua Bio
    • 企業簡介
    • 業績
    • 未來發展
  • Global Bio-Chem
    • 企業簡介
    • 業績
    • 未來發展
  • 結論

第3章 海外企業

  • Evonik
    • 企業簡介
    • 業績
    • 未來發展
  • Ajinomoto
    • 企業簡介
    • 業績
    • 未來發展
  • CJ CheilJedang
    • 企業簡介
    • 業績
    • 未來發展
  • 結論

圖表

目錄

Amino acid industry hot topics since 2013:

  • Capacity of bulk amino acids (especially lysine and methionine) continued to increase in the world, intensifying the competition in global market.
  • Due to increasing competition and weak demand, the market of bulk amino acids in China continued in recession.
  • Leading producers of bulk amino acids started to cut production since end 2013, and the price of bulk amino acids saw rebound since Q2 2013.

Purpose of report:

CCM has analyzed the performance and management plans of both domestic and overseas leading producers of amino acids, in order to make a comparison of domestic and overseas enterprises, and give a future pattern of global amino acid industry.

What to report:

In this report, business directions of leading amino acid producers are analyzed from the following aspects:

  • Performance of producers by segment and region;
  • Some key projects;
  • Some important dynamics;
  • Future management plans.

Forecasts:

  • Competition in global lysine market is becoming more intense following the launch of many new capacities in China and the US. Integration of lysine industry will be improved therefore.
  • Global distribution of methinone production will be more balanced after the completion of some new capacities in Asia, including plants of Evonik and CJ Group.
  • Minor amino acids may be considered as new growth point for domestic producers, because of their higher profitability than bulk products.

Table of Contents

1. Overview

2. Domestic enterprises

  • 2-1. Fufeng Group
    • 2-1-1. Company profile
    • 2-1-2. Performance
    • 2-1-3. Future development
  • 2-2. Meihua Bio
    • 2-2-1. Company profile
    • 2-2-2. Performance
    • 2-2-3. Future development
  • 2-3. Global Bio-Chem
    • 2-3-1. Company profile
    • 2-3-2. Performance
    • 2-3-3. Future development
  • 2-4. Conclusions

3. Oveaseas enterprises

  • 3-1. Evonik
    • 3-1-1. Company profile
    • 3-1-2. Performance
    • 3-1-3. Future development
  • 3-2. Ajinomoto
    • 3-2-1. Company profile
    • 3-2-2. Performance
    • 3-2-3. Future development
  • 3-3. CJ CheilJedang
    • 3-3-1. Company profile
    • 3-3-2. Dynamics and future development
  • 3-4. Conclusions

List of Tables:

  • Table 2.1.2-1: Performance of high grade amino acids of Fufeng Group, 2012-H1 2014
  • Table 2.1.2-2: Performance of Fufeng Group's threonine and lysine business, 2012-H12014
  • Table 2.2.3-1: Main investment projects of Meihua Bio since 2013
  • Table 2.3.2-1: Performance of Global Bio-chem, 2013
  • Table 2.3.2-2: Performance of Global Bio-chem by product, 2012 and 2013
  • Table 3.1.3-1: Projects under construction of Evonik, 2013
  • Table 3.2.2-1: Net sales and operating profit of Ajinomoto by segment in FY2013 (ended March 31, 2014), billion JPY
  • Table 3.2.2-2: Net sales and operating profit of Ajinomoto by region in FY2013 (ended March 31, 2014), billion JPY
  • Table 3.2.3-1: Performance of Ajinomoto, 2011-2020
  • Table 3.2.3-2: Market size of feed-use amino acids and shares of Ajinomoto, 2010-2014, 000' tonne

List of Figures:

  • Figure 2.1.2-1: Revenue of Fufeng Group by business unit, 2013
  • Figure 2.1.2-2: Average selling price of MSG of Fufeng Group, 2011-H1 2014, USD/t
  • Figure 2.1.2-3: Sales volume and average selling price of Fufeng Group's xanthan gum, 2010-H1 2014
  • Figure 2.1.3-1: Revenue growth of Fufeng Group by business unit, 2013 and H1 2014, million USD
  • Figure 2.2.2-1: Revenue and gross profit of Meihua Bio by product, 2013
  • Figure 2.2.2-2: Revenue of Meihua Bio by segment, 2010-2013, million USD
  • Figure 2.2.2-3: Gross profit and gross profit margin of Meihua Bio by segment, 2010-2013, million USD
  • Figure 2.2.2-4: Ex-works prices of Meihua Bio's monosodium glutamate (MSG), threonine, and lysine, 2012-2013, USD/t
  • Figure 2.2.2-5: Ex-works prices of Meihua Bio's minor amino acids, 2012-2013, USD/t
  • Figure 2.3.2-1: Revenue structure of Global Bio-chem by product, 2013
  • Figure 3.1.2-1: Sales of Evonik by region in 2013, in USD million
  • Figure 3.1.2-2: Capital expenditure of Evonik by region in 2013, in USD million
  • Figure 3.1.3-1: External sales, adjusted EBIT, EVA, and capital expenditure of Evonik by segment, in million USD, 2013
  • Figure 3.2.3-1: Ratio of retailed monosodium glutamate, by slaes volume, 2013-2020
  • Figure 3.2.3-2: Ratio of retailed sweetener, by slaes value, 2013-2020
  • Figure 3.2.3-3: Operating profit of feed-use amino acids, billion JPY
  • Figure 3.4-1: Layout of the plants of Evonik, Ajinomoto and CJ CheilJedang, for feed-use amino acids
Back to Top